COEP

Coeptis Therapeutics, Inc. NASDAQ Listed Dec 17, 2020

Healthcare ·Biotechnology ·US · coeptispharma.com

$5.60

-22.22% vs $7.20

Mkt Cap $23.7M

52w Low $5.60 0.0% of range 52w High $18.80

50d MA $11.96 200d MA $13.65

P/E (TTM) -2.3x

EV/EBITDA —

P/B 1.3x

Debt/Equity 0.0x

ROE -87.9%

P/FCF -2.8x

RSI (14) 23.30

ATR (14) $1.67

Beta -0.43

50d MA $11.96

200d MA $13.65

Avg Volume 650.1K

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

SIC Code

6199

CIK (SEC)

1759186

Phone

724 934 6467

105 Bradford Road · Wexford, PA 15090 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	-0.80	-0.12	+85.0%	11.30	-2.6%	+0.0%	-2.1%	-6.0%	+7.6%	-2.4%	—
Nov 13, 2025	AMC	—	-0.58	—	14.15	+0.0%	+2.9%	+4.1%	+12.2%	-6.1%	+2.2%	—
Aug 14, 2025	AMC	—	-1.17	—	11.48	+4.5%	+21.7%	+4.9%	-7.4%	+0.3%	-1.3%	—
May 14, 2025	AMC	—	-1.11	—	9.31	-0.9%	+3.0%	+2.3%	-0.9%	-0.6%	+1.6%	—
Mar 28, 2025	AMC	-0.80	-1.01	-26.5%	9.38	-0.1%	-0.1%	+1.1%	+0.1%	+2.8%	-0.8%	—
Nov 13, 2024	AMC	-0.05	-0.05	+0.0%	3.86	+6.7%	+6.7%	-3.4%	-1.5%	-0.5%	-0.5%	—
Aug 16, 2024	AMC	-0.09	-0.08	+11.1%	4.04	+6.4%	+5.0%	+1.4%	-1.4%	-3.3%	+0.0%	—
May 10, 2024	AMC	—	-0.08	—	7.66	-0.8%	-7.0%	+2.0%	-2.2%	+0.0%	-1.4%	—
Mar 26, 2024	AMC	—	-0.11	—	6.00	+3.3%	-1.0%	+0.0%	-0.7%	+6.8%	+1.3%	—
Nov 9, 2023	AMC	—	-0.23	—	20.60	+3.9%	+6.8%	-1.8%	+7.4%	+6.9%	+4.0%	—
Aug 11, 2023	AMC	-0.12	-0.08	+33.3%	22.20	+2.3%	+0.0%	+0.0%	-2.7%	+1.9%	-3.6%	—
May 15, 2023	AMC	—	-0.46	—	33.20	+2.4%	+1.2%	+3.0%	+5.8%	+8.2%	+8.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 18	EF Hutton	Maintains	Buy → Buy	—	$34.60	$33.80	-2.3%	+5.8%	+8.2%	+8.1%	-13.1%	+3.8%

Data updated apr 25, 2026 2:29am · Source: financialmodelingprep.com